Cargando…

Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy

INTRODUCTION: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine reuptake inhibitor (SNRI) recently approved for the treatment of major depressive disorder. It is one of only three medications in this class available in the United States. AIMS: The objective of this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lieberman, Daniel Z, Massey, Suena H
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899788/ https://www.ncbi.nlm.nih.gov/pubmed/20694066

Ejemplares similares

Desvenlafaxine in the treatment of major depressive disorder
por: Lourenco, Maria Teresa C, et al.
Publicado: (2009)

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder
por: Atkinson, Sarah, et al.
Publicado: (2018)

Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
por: Hellerstein, David J, et al.
Publicado: (2015)

Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine
por: Benoit, James R.A., et al.
Publicado: (2021)

Desvenlafaxine
por: Andrade, Chittaranjan
Publicado: (2009)

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder
por: Weihs, Karen L., et al.
Publicado: (2018)

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
por: Katzman, Martin A., et al.
Publicado: (2017)

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study
por: Roh, Sungwon, et al.
Publicado: (2022)

PS210. Effect of Desvenlafaxine on Altered Heart Rate Variability in Persistent Depressive Disorder
por: Ravindran, Arun V., et al.
Publicado: (2016)

Desvenlafaxine Extended-Release in Panic Disorder: A Retrospective Chart Review
por: Min Lee, Sang, et al.
Publicado: (2022)

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine
por: Soares, Claudio N., et al.
Publicado: (2019)

PS100. Open-label Desvenlafaxine as Monotherapy for Persistent Depression Disorder: A Pilot Study
por: Ravindran, Arun V., et al.
Publicado: (2016)

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
por: Bousman, Chad A., et al.
Publicado: (2017)

Periodontal status in chronic periodontitis depressed patients on desvenlafaxine: An observational study
por: Bhatia, Anu, et al.
Publicado: (2018)

A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
por: Ch, Saritha, et al.
Publicado: (2022)

Desvenlafaxine-Induced Interstitial Pneumonitis: A Case Report
por: Flora, Arjan, et al.
Publicado: (2018)

Desvenlafaxine-associated hyperglycemia: A case report and literature review
por: Mekonnen, Andrea D., et al.
Publicado: (2020)

Venlafaxine and desvenlafaxine in the management of menopausal hot flashes
por: Johnson, Emily D, et al.
Publicado: (2011)

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder
por: Liebowitz, Michael R, et al.
Publicado: (2013)

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression
por: Zilcha-Mano, Sigal, et al.
Publicado: (2021)

Micafungin: an evidence-based review of its place in therapy
por: de la Torre, Pola, et al.
Publicado: (2014)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Drug–drug interactions involving antidepressants: focus on desvenlafaxine
por: Low, Yvette, et al.
Publicado: (2018)

Multidisciplinar treatment in postpartum depression. Coordinated attention of psychiatrist and midwife: use of desvenlafaxine while breastfeeding
por: Sánchez Rus, S.S., et al.
Publicado: (2022)

Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial
por: Gupta, Brij Mohan, et al.
Publicado: (2016)

Agomelatine: The evidence for its place in the treatment of depression
por: Eser, Daniela, et al.
Publicado: (2010)

Prenatal desvenlafaxine induced behavioural alterations in Swiss albino mice
por: Kumari, Amrita, et al.
Publicado: (2014)

Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets
por: Carapeto, Gustavo Vaiano, et al.
Publicado: (2023)

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial
por: Maity, Nabakumar, et al.
Publicado: (2014)

Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy
por: Hennigan, Stephanie, et al.
Publicado: (2007)

Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy
por: Tonin, Fernanda S, et al.
Publicado: (2016)

Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy
por: Allen, Rob, et al.
Publicado: (2014)

LC–UV and LC–MS evaluation of stress degradation behavior of desvenlafaxine
por: Pawar, Shubhangi M., et al.
Publicado: (2012)

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets
por: Samy, Wael, et al.
Publicado: (2017)

Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery
por: Tong, Gui-Feng, et al.
Publicado: (2017)

Pre-pregnancy Body Mass Index and Third-Trimester Depressive Symptoms in a Healthy Privately Insured Sample
por: Schuette, Stephanie A., et al.
Publicado: (2018)

Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy
por: Dinnel, Jennifer, et al.
Publicado: (2015)

Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
por: Graff, Julie N, et al.
Publicado: (2014)

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy
por: Angeloni, Emiliano
Publicado: (2016)

Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy
por: Jang, Ji Hye, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nsun2pcjvba9ci2r7n0sr9ciu2